Biotech
AstraZeneca Revives COPD Drug Class with Strong Phase 3 Results
AstraZeneca reports strong phase 3 results for its COPD drug tozorakimab, showing consistent efficacy where rival IL-33 therapies failed.
S
Surya Pratap Singh
3/29/2026, 6:46:44 AM
